Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FADS1 | O60427 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MGAT2 | Q10469 | 3/20 | 0.31 |
| ▸ | LIPE | Q05469 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2561992 | 0.89 | ALDH1A1 (0.43) | FADS1TSHRALDH1A1KMT2AGAA | |
| SCHEMBL2566730 | 0.85 | FADS1 (0.42) | FADS1TSHRALDH1A1KMT2AGAA | |
| SCHEMBL2561188 | 0.85 | FADS1 (0.42) | FADS1TSHRALDH1A1KMT2AGAA | |
| SCHEMBL2565032 | 0.85 | TSHR (0.45) | FADS1TSHRALDH1A1KMT2AGAA | |
| SCHEMBL13257671 | 0.84 | MEN1 (0.37) | TSHRALDH1A1KMT2AGAAMEN1 | |
| SCHEMBL2997555 | 0.83 | FADS1 (0.46) | FADS1TSHRALDH1A1KMT2AGAA | |
| SCHEMBL2563697 | 0.83 | TSHR (0.46) | FADS1TSHRALDH1A1KMT2AGAA | |
| SCHEMBL2566655 | 0.83 | FADS1 (0.40) | FADS1TSHRALDH1A1KMT2AGAA | |
| SCHEMBL2561305 | 0.82 | MEN1 (0.42) | FADS1TSHRALDH1A1KMT2AGAA | |
| SCHEMBL2566985 | 0.82 | FADS1 (0.42) | FADS1TSHRALDH1A1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190747-A1 | Fused ring compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-29 | — | — | US | disclosed |
| US-20100190747-A1 | Fused ring compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-29 | — | — | US | disclosed |
| US-20100190747-A1 | Fused ring compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190747-A1 | Fused ring compound and use thereof | CYP46A1, LTB4R2, PTGES | FADS1 140/4885TSHR 4543/4885ALDH1A1 875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.